Publications by authors named "A L Lecourt"

Background And Objectives: In patients with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), acute disease activity is generally identified through medical history, neurologic examination, and imaging. However, these may be insufficient for detecting disease activity in specific conditions. This study aimed to investigate the dynamics of serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) after clinical attacks and to assess their utility in discriminating attacks from remission in patients with MOGAD.

View Article and Find Full Text PDF

Importance: Differential diagnosis of patients with seronegative demyelinating central nervous system (CNS) disease is challenging. In this regard, evidence suggests that immunoglobulin (Ig) A plays a role in the pathogenesis of different autoimmune diseases. Yet little is known about the presence and clinical relevance of IgA antibodies against myelin oligodendrocyte glycoprotein (MOG) in CNS demyelination.

View Article and Find Full Text PDF

Introduction: There is no consensus for management of Mild primary hyperparathyroidism (MILD-pHP). Specific management has been suggested by some authors. We have compared the surgical management of the patients with MILD-pHP to those with Classic primary hyperparathyroidism (C-pHP) treated by surgery according to The Fourth International Workshop on pHP.

View Article and Find Full Text PDF

This case report is about a 51-year-old active duty male with JAK2 mutation and medical history significant for prehepatic portal hypertension from portal vein thrombus on lifelong anticoagulation with rivaroxaban, an oral factor Xa inhibitor, presenting with closed-loop small bowel obstruction requiring emergent laparotomy. We present this surgical case as it required emergent reversal of the oral factor Xa inhibitor with andexanet alfa.

View Article and Find Full Text PDF
Article Synopsis
  • A study analyzed young breast cancer survivors' desire for pregnancy post-treatment, focusing on the time it takes to achieve pregnancy and outcomes for both mothers and babies.
  • The research included 133 patients aged 18-43, who had a total of 197 pregnancies, finding that 71% were planned and a significant proportion resulted in live births.
  • Results showed a median time of 48 months from breast cancer diagnosis to pregnancy, with no significant negative impact of cancer treatments on obstetrical or neonatal outcomes, providing encouraging information for patients considering pregnancy.
View Article and Find Full Text PDF